Pfizer, Adolor ink pain drug deal

Continuing on its deal-making quest, Pfizer has signed an agreement with Exton, PA-based Adolor for ADL5859 and ADL5747. The two pain drugs treat a range of conditions, including inflammatory pain and neuropathic pain. ADL5859 is currently in Phase II trials and ADL5747 is set to begin Phase I trials in the first quarter of 2008. Adolor gains an upfront payment of $30 million along with $1.9 million reimbursement for previous development costs. The company could earn up to $232.5 million in milestone payments.

"This collaboration demonstrates our commitment to executing against the R&D plan we outlined, including expanding our Phase 2 portfolio with a strong focus in our key therapeutic areas," said Dr. Martin Mackay, president of Pfizer Global Research and Development. "Pfizer has a strong history in bringing to market novel pain solutions including Lyrica, Neurontin and Celebrex. However, there still remains a significant unmet medical need for patients suffering from a variety of debilitating pain conditions."

- see this release for more

ALSO: Take a look at Pfizer's pipeline. Report

Related Articles:
Speculation soars over Pfizer's interest in biotech. Report
Pfizer tops the charts in global R&D spending. Report
Pfizer hires new R&D chief, launches biotech center. Report
Investors cheer FDA's acceptance of Adolor's Entereg response. Report